JNK inhibitors (e.g., JNK-IN-8) showed cytotoxicity in T-ALL cell lines with IC50 > 10 μM by inhibiting the MAP2K7-JNK pathway (58, 59). This evidence concerns the gene MAPK8 and acute lymphoblastic leukemia.